2024-06-17 09:13:40 ET
Summary
- Viking Therapeutics shows promise with their VK2735 drug demonstrating significant weight loss in Phase 2 trials.
- Despite strong data, Viking faces intense competition and strategic challenges in a market dominated by Novo Nordisk and Eli Lilly.
- Viking’s financials are solid, with a substantial cash runway, but escalating costs could pose future risks as they advance to later-stage trials.
- I recommend Viking Therapeutics as a high-risk/high-reward investment suitable for a barbell investment strategy.
Viking Therapeutics: Weighing the Future of Weight Loss
I last covered Viking Therapeutics ( VKTX ) in March within an overview of the obesity treatment landscape . I was encouraged by Viking's subcutaneous GLP-1/GIP dual agonist, VK2735 . Phase 2 data demonstrated robust weight loss, with 35 patients losing 13.1% (placebo-adjusted) of their baseline weight after just 13 weeks. In March, Viking revealed data for their oral , once-daily GLP-1/GIP dual agonist. Placebo-adjusted weight loss was 3.3% after 34 days. So, Viking is positioning themselves to take advantage of, what could be, a $130 billion market by 2030. Of course, Novo Nordisk ( NVO ) and Eli Lilly ( LLY ) are the leaders in this market with their subcutaneous GLP-1 (Wegovy) and GLP-1/GIP (Zepbound) agonist offerings, respectively. Neither company's production can meet the demand. Both Novo Nordisk and Eli Lilly are investing billions of dollars to boost production....
Read the full article on Seeking Alpha
For further details see:
Viking Therapeutics: A Contender In The Growing Obesity Treatment Landscape